ATLANTA, Feb. 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., president and chief executive officer, will present a corporate update at the 12th Annual BIO CEO & Investor Conference. The presentation will take place at 1:00 p.m. Eastern Time on February 9, 2010 at the Waldorf Astoria Hotel in New York City.
Dr. McNally commented, "This Conference offers GeoVax many opportunities including updating attendees on our progress on both preventative and therapeutic human vaccine trial fronts, and meeting with potential partners, investors and analysts. We look forward to the opportunity."
About HIV/AIDS
AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally and it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the US is infected with AIDS. Globally, HIV is the top killer among women of reproductive age.
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent acquisition of HIV-1 and limit the progression to AIDS should a person become infected GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).
GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $18 million IPCAVD grant awarded in late 2007.
GeoVax Labs, Inc.
